Dermatologicals
Refine Search
Biotechnology
Colorado, USA-based biotech Enveda Biosciences, which is using AI to translate nature into new medicines, has announced an oversubscribed $130 million Series C funding round led by Kinnevik and FPV. 22 November 2024
Biotechnology
The landscape of atopic dermatitis (AD) treatment is advancing with approvals of oral and topical Janus kinase (JAK) inhibitors across the seven major pharmaceutical markets (7MM; USA, France, Germany, Italy, Spain, UK and Japan). 20 November 2024
Biotechnology
Johnson & Johnson and partner Protagonist Therapeutics have reported positive topline results from two Phase III studies testing a first-in-class oral peptide. 20 November 2024
Biotechnology
Aclaris Therapeutics has announced an exclusive licensing agreement with Biosion for broad rights to two new antibodies. 19 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental Biologics License Application (sBLA) for Dupixent(dupilumab), Regeneron and partner Sanofi revealed late Friday. 18 November 2024
Pharmaceutical
Danish dermatology specialist LEO Pharma today announced that Swissmedic, Switzerland’s national regulatory agency for approving and overseeing therapeutic products, has granted marketing approval for Anzupgo (delgocitinib) cream. 14 November 2024
Biotechnology
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
Pharmaceutical
Almirall, the Spain-based biopharma, reported a 7.9% increase in net sales for the first nine months of 2024, reaching 728 million euros ($775 million), and an EBITDA rise of 2.9% to $152 million. 11 November 2024
Biotechnology
New research has been published in the Journal of Allergy and Clinical Immunology (JACI) that shows treatment with amlitelimab, an anti-OX40 ligand antibody, significantly reduced symptoms of atopic dermatitis (AD) and was maintained even after treatment stopped. 9 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted a Rare Pediatric disease designation for BPM31510T, an investigational treatment for epidermolysis (EB) from BPGbio. 4 November 2024
Pharmaceutical
Denmark’s privately-held dermatology specialist LEO Pharma and Japan’s Kyowa Kirin have revealed that they will terminate the distribution and co-promotion agreement for the psoriasis vulgaris treatment Dovobet Ointment, Gel, and Foam (calcipotriol hydrate / betamethasone dipropionate) in Japan on December 31, 2024. 1 November 2024
Biotechnology
Regeneron Pharmaceuticals today announced financial results for the third quarter of 2024 that beat expectations, but still saw its share price fall more than 6% to $866 in early trading. 31 October 2024
Biotechnology
Treatment with Tremfya (guselkumab) resulted in clear or almost clear skin in the majority of adults with low body surface area (BSA) moderate plaque psoriasis (PsO) with special site involvement who had failed topical treatment, says US healthcare giant Johnson & Johnson. 25 October 2024
Biotechnology
New results show Eli Lilly Ebglyss (lebrikizumab-lbkz) improved skin (including hand and face) and itch among patients with moderate-to-severe atopic dermatitis (eczema) who were previously treated with Dupixent (dupilumab). 25 October 2024
Biosimilars
Iceland-based Alvotech and the US unit of Israel’s of Teva Pharmaceutical Industries today revealed that that the US Food and Drug Administration (FDA) has approved Selarsdi (ustekinumab-aekn) in a new presentation 22 October 2024
Pharmaceutical
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
The US Food and Drug Administration (FDA) has approved a 2mL pre-filled syringe and pre-filled autoinjector, each containing 320mg of Belgian drugmaker UCB’s Bimzelx (bimekizumab-bkzx), to treat psoriasis. 14 October 2024
Biosimilars
Bio-Thera Solutions and Hungary’s Gedeon Richter have reached an exclusive commercialization and license agreement. 14 October 2024
Biotechnology
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Biotechnology
Results from the Phase III STYLE study show that Otezla (apremilast) 30mg twice daily achieved a highly statistically-significant improvement in the primary endpoint of the Scalp Physician’s Global Assessment (ScPGA) response [defined as ScPGA score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline] at week 16 compared with placebo. 9 October 2018
Pharmaceutical
Nifuroxazide is an oral antibiotic used to treat colitis and diarrhea that was first patented 52 years ago. 4 October 2018
Pharmaceutical
US biopharma firm Paratek Pharmaceuticals (Nasdaq: PRTK) was on the receiving end of good news yesterday, as the US Food and Drug Administration approved its acne drug Seysara (sarecycline). 4 October 2018
Pharmaceutical
Cambridge, Massachusetts-based drug developer Boston Pharmaceuticals today announced two separate licensing deals with leading pharma companies. 3 October 2018
Pharmaceutical
Hot on the heels of its approval in Europe, the Australian Therapeutic Goods Administration (TGA) has given the green light to Ilumya (tildrakizumab) for moderate-to-severe plaque psoriasis patients who are candidates for systemic therapy. 24 September 2018
Pharmaceutical
Among last week’s regulatory events, new of US Food and Drug Administration approval of Teva Pharmaceutical Industries’ migraine prophylaxis drug Ajovy (fremanezumab) is seen as a turning point for the Israeli company. There was also FDA approval for AstraZeneca’s leukemia drug Lumoxiti, and the agency lifted the partial clinical hold on Mersana’s XMT-1522 cancer drug, but the company’s shares fell. Allergan’s acquisition of medical aesthetics firm Bonti is seen as good news for the firm. On the research front, Viking Therapeutics soared on strong clinical data for its liver disease drug VK2809, but it may not be the first to come to the market. 23 September 2018
Pharmaceutical
Spain’s largest drugmaker Almirall has entered a deal that could potentially as much as $665 million to acquire a portfolio of dermatologic products for the US market. 21 September 2018
Pharmaceutical
The roll-out of Ilumetri (tildrakizumab) is to take place over the next few weeks following European Commission approval of the humanized high-affinity anti-IL-23p19 monoclonal antibody. 19 September 2018
Biotechnology
Spain’s largest drugmaker is the latest pharma company to announce a collaboration with German biotech Evotec. 18 September 2018
Pharmaceutical
Allergan on Friday announced it is expanding its already successful Botox medical aesthetics business with the acquisition of Bonti, a privately held clinical-stage biotechnology company. 17 September 2018
Biotechnology
Data presented at the 27th European Academy of Dermatology and Venereology (EADV) in Paris, France, show that treatment with Kyntheum (brodalumab) for people with moderate to severe plaque psoriasis, was associated with a more rapid reduction in absolute Psoriasis Area Severity Index (PASI) scores and a greater probability of achieving complete skin clearance in all body regions compared with ustekinumab. 14 September 2018
Biosimilars
As AbbVie continues to fend of biosimilars competition in the USA for to its mega-blockbuster drug Humira (adalimumab), new data presented at the European Association of Dermatology and Venereology Annual Meeting (EADV 2018) in Paris further support another strong competitor. 12 September 2018
Generics
Months after reports indicated that Aurobindo Pharma would bid for the generics firm Sandoz, parent company Novartis announced it had accepted an offer of around $1 billion from the Indian drugmaker. 7 September 2018
Pharmaceutical
New Zealand’s Pharmaceutical Management Agency PHARMAC has announced a major funding package involving ten medicines in seven key therapy areas through an agreement with Swiss pharma giant Novartis. 6 September 2018
Biotechnology
Promore Pharma, a Swedish developer of therapeutic peptides, plans to expand the indications of its lead compound, the anti-adhesion and anti-scarring agent PXL01, to explore the feasibility of using the compound for the prevention of dermal scarring. 3 September 2018
Pharmaceutical
The global orphan and rare dermatology premium products market is expected to grow rapidly from $1.64 billion in 2017 to $6.07 billion in 2024, at a compound annual growth rate (CAGR) of 20.5%. 3 September 2018
Pharmaceutical
Denmark's LEO Pharma, the privately-held dermatology specialist, announced on Friday that it had reached an agreement with Korean pharma firm JW Pharmaceutical to license JW1601, a dual-action antihistamine. 24 August 2018
Pharmaceutical
A privately-held Danish company that is developing topical therapies for skin and eye diseases has announced positive Phase III data on its MC2-01 Cream (calcipotriene and betamethasone dipropionate). 22 August 2018
Biotechnology
A trial failure for the UK-based biopharmaceutical firm Realm Therapeutics (LSE: RLM) has led to its share price dropping to less than half of the level that it started the week at. 15 August 2018
Biotechnology
With Sanofi and Regeneron’s Dupixent (dupilumab) dominating the current standard of care in atopic dermatitis, new monoclonal antibody (MAb) treatments such as Novartis’ MOR106 are unlikely to overthrow it, says analyst. 10 August 2018
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze